BBNX vs PODD
BBNX: Beta Bionics is a medical technology company developing automated insulin delivery systems to simplify diabetes management and improve patient outcomes. PODD: Insulet provides the Omnipod system, a revolutionary tubeless, wearable insulin pump platform that simplifies diabetes management through automated insulin delivery.
Side-by-side fundamentals
| Metric | BBNX | PODD | Edge |
|---|---|---|---|
| Price as of 2026-10-20 close | $17.74 | $142.64 | |
| Market cap | $798M | $9.9B | |
| P/E as of 2026-10-20 | n/a | 26.76 | |
| Net margin FY2025, SEC XBRL | -73.0% | +9.1% | PODD higher |
| Gross margin FY2025, SEC XBRL | +55.4% | +71.6% | PODD higher |
| Operating margin FY2025, SEC XBRL | -71.5% | +17.5% | PODD higher |
| ROE FY2025, SEC XBRL | -25.5% | +16.3% | PODD higher |
| ROA FY2025, SEC XBRL | -22.3% | +7.7% | PODD higher |
| Debt / equity filed borrowings incl. finance leases, balance sheet 2026-06-30 | n/a | 0.67 | |
| Revenue growth (YoY) FY2025, SEC XBRL | +53.9% | +30.7% | BBNX higher |
| Revenue CAGR (3y) SEC XBRL | +189.1% | +27.5% | BBNX higher |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 1.68 | 0.65 | |
| 1-year return as of 2026-10-20 close | -12.4% | -56.4% | BBNX higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.